(CNBC) – One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to one of Wall Street’s major investment banks. Bank of America Merrill Lynch analysts Felix Tran and Haim Israel believe that genome sequencers such as Illumina, high-tech players such as Alphabet and biotech
companies such as Novartis are on the cusp of “bringing unprecedented increases to the quality and length of human lifespans.” Innovation in genome science, big data and “ammortality,” which includes wearable technology and products in the so-called wellness space, could soon prolong healthy human life well beyond 100 years, BofA told clients Wednesday. “Medical knowledge will double every 73 days by 2020 vs. every 3.5 (years) in 2010, and genomic sequencing costs have fallen 99.999% since 2003,” Israel and Tran wrote. READ MORE
